Baxter Healthcare

What Baxter Healthcare does

Baxter Healthcare Limited is a UK-incorporated subsidiary of Baxter International Inc. (NYSE: BAX), a global medical technology company founded in 1931 and headquartered in Deerfield, Illinois. The company develops, manufactures, and supplies medical devices, pharmaceutical products, and digital health solutions across five primary care areas: hospital care (advanced infusion systems, IV solutions, premixed drugs, and anaesthesia gases), nutritional care (clinical nutrition for patients unable to feed orally or enterally, including home parenteral nutrition), critical and renal care (continuous renal replacement therapy systems, peritoneal dialysis solutions, and automated PD devices), surgical care (haemostats, sealants, and adhesion reduction products), and home care (self-administered OPAT and home dialysis pathways enabled by patient education centres in Swinton and Kew).

The technology platform is anchored by proprietary systems including the PRISMAX System (CRRT, therapeutic plasma exchange, and extracorporeal CO2 removal), SHARESOURCE remote connectivity platform for home peritoneal dialysis, the PrismaLung+ ECCO2R device, and the Cybersecurity Common Controls Framework for Medical Devices (C3FMD). The portfolio was materially expanded in December 2021 through the $10.5 billion acquisition of Hillrom, which added Welch Allyn diagnostic equipment, patient monitoring, and connected care technologies, bringing the combined installed base to more than 2 million medical devices globally. In 2024, Baxter spun off its kidney care business as the independent company Vantive, reshaping the continuing entity's footprint. Baxter operates 13 UK sites including three manufacturing facilities, four aseptic compounding facilities, distribution centres, and patient education academies, supplying 7,500+ products to the NHS and serving patients across more than 100 countries.

Baxter generates revenue primarily through direct enterprise sales of hardware and pharmaceutical products to hospitals, NHS trusts, and healthcare providers under quote-based multi-year contracts, with a growing recurring component from digital health and remote monitoring services. Following the Hillrom combination, Baxter positioned itself as a ~$15 billion global medtech leader, targeting $250 million in annual pre-tax cost synergies by year three, high single-digit ROIC by year five, and more than 20% accretion to adjusted EPS by year three. Go-to-market relies on enterprise field sales to hospitals and NHS organisations, joint working agreements with clinical networks and alliances, channel partnerships through NHS procurement, and direct-to-patient home therapy distribution managed through NHS commissioning.

Name

Baxter Healthcare

Legal name

Baxter Healthcare Limited

Website

https://baxterhealthcare.co.uk

Company type

Public

Founded year

1931

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Baxter Healthcare is the UK subsidiary of Baxter International Inc., supplying medical devices, pharmaceutical products, and digital health solutions across hospital, nutritional, renal, critical, and surgical care to the NHS, hospitals, and patients in 100+ countries.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Home Health Care Services (621610), Ambulatory Health Care Services (621)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Infusion & Home Infusion Pharmacy Services (HLAFALAG)

akta.pro secondary industries

Home Infusion Therapy Providers (HLAFAEAE), IV Therapy, Infusion & Injection Services (Home-Based) (HSABACAF), Injectables & Specialty Medication Support (e.g., insulin, biologics) (HSABALAG), Home Infusion Therapy & IV Nursing Services (HLADAFAG)

Keywords

• Medical devices
• Infusion systems
• Renal care products
• Clinical nutrition
• Surgical haemostats

Headquarters

HQ city

Newbury

HQ country

United Kingdom

HQ region

Europe

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Medical Devices and Hardware Sales: Sale of infusion systems, dialysis equipment, surgical products, and other medical devices. Products include advanced infusion systems, anaesthetic gases, premixed drugs, pharmacy and infusion technologies found in hospitals and clinics worldwide.
2. Pharmaceutical Products: Intravenous solutions, clinical nutrition products, and pharmaceutical formulations for hospital and home care settings.
3. Digital Health Solutions and Services: Connected care technologies, remote patient monitoring through platforms like SHARESOURCE, and associated software and service offerings.
4. Hillrom Product Portfolio Integration: Following the $10.5 billion acquisition of Hillrom (December 2021), Baxter expanded its portfolio to include patient monitoring, diagnostic, and respiratory care devices, creating a combined company supporting millions of patients across homes, physician offices, ambulatory care centers, and nearly every hospital department.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Baxter Healthcare manufactures and supplies medical devices, IV solutions, infusion systems, clinical nutrition products, renal care therapies, surgical haemostats and sealants, and connected care/digital health solutions to hospitals, NHS organisations, and home care patients across more than 100 countries. Its portfolio spans hospital care, critical care, nutritional care, renal care, and surgical care applications, including proprietary systems such as PRISMAX (CRRT), HOMECHOICE and AMIA with SHARESOURCE (home peritoneal dialysis), and the Hillrom-acquired patient monitoring and diagnostic range.

Product overview

Baxter Healthcare operates as a diversified medical technology company offering a unified platform of hospital, nutritional, renal, critical care, and surgical care products. The portfolio includes advanced infusion systems and IV solutions (VIAFLEX, MINI-BAG), continuous renal replacement therapy systems (PRISMAX), peritoneal dialysis solutions and automated systems (HOMECHOICE, KAGUYA, AMIA with SHARESOURCE), haemostatic agents and sealants (FLOSEAL, TISSEEL, HEMOPATCH), clinical nutrition products, and connected care/digital health solutions. Following the 2021 acquisition of Hillrom, the company expanded to include patient monitoring and diagnostic equipment (Welch Allyn). With products available in more than 100 countries and over two million connected medical devices globally, Baxter serves patients across homes, hospitals, physician offices, and alternate care settings. The company maintains over 13 UK sites including manufacturing facilities, distribution centers, and patient education centers.

Differentiator

Problem solved

Functional benefit

Brands

• PRISMAX System: Critical care system designed to provide individualized and effective therapies for critically ill patients on the intensive care unit, including CRRT, TPE, and ECCO2R therapies.
• Hillrom
• Vantive

Products and services

• PRISMAX System Advanced control unit for continuous renal replacement therapy (CRRT), therapeutic plasma exchange (TPE), and extracorporeal CO2 removal (ECCO2R) in intensive care settings, providing individualised therapies for critically ill patients with acute kidney injury.
• Hospital Care Products Intravenous solutions, anaesthetic gases, premixed drugs, pharmacy and infusion technologies designed to enable safe medication administration and reduce preventable drug errors in hospital settings.
• Surgical Care Products Haemostatic agents, sealants, and adhesion reduction products used to reduce complications from bleeding, fluid leakage and adhesions during and after surgery.
• Nutritional Care Products Clinical nutrition solutions including home parenteral nutrition (HPN) therapy for patients who cannot adequately feed themselves orally or enterally.
• Renal Care Products Kidney care products including peritoneal dialysis solutions, automated PD systems, and HDx therapy enabled by THERANOVA for patients with end-stage renal disease.
• AMIA with SHARESOURCE Automated peritoneal dialysis (APD) system with SHARESOURCE remote connectivity platform enabling home peritoneal dialysis therapy with clinical oversight.
• KAGUYA APD System Automated peritoneal dialysis (APD) system designed for Japanese renal patients, reflecting local needs and demographics.
• FLOSEAL Haemostatic Agent Haemostatic agent for managing bleeding during surgical procedures.
• TISSEEL Fibrin Sealant First fibrin sealant approved in the U.S., used for tissue sealing during surgery including adhering skin grafts in burn patients (ARTISS variant).
• HEMOPATCH Sealing Hemostat Resorbable collagen-based pad and sealing hemostat for controlling bleeding in various surgical scenarios.
• THERANOVA Dialyser Dialyser featuring an innovative membrane providing expanded haemodialysis therapy (HDx) for patients with end-stage renal disease.
• Connected Care / Digital Health Solutions Digital health technologies and connectivity solutions that integrate with hospital infrastructure to deliver clinical insights to care teams, including SHARESOURCE remote patient monitoring.
• Hillrom Patient Monitoring and Diagnostic Products Patient monitoring, vital signs assessment, and connected care devices including Welch Allyn diagnostic equipment, serving hospital, home and alternate care settings.

Quantifiable outcome

• Self-administered OPAT reduces CO2 emissions by 85% compared with in-hospital IV antibiotic treatment
• +5 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

25 partnerships are on record, tiered core and minor.

• University Hospitals Coventry and Warwickshire (UHCW) NHS TrustcoreStrategic or Co-development Partner · 19 December 2025Baxter collaborated with UHCW NHS Trust and Environmental Resources Management (ERM) to publish a first-of-its-kind report on the environmental impact of OPAT care pathways. The study demonstrated significant environmental benefits including 85% CO2 reduction, 78% water usage reduction, and 91% waste reduction for home-based versus in-hospital treatment.
• Environmental Resources Management (ERM)coreStrategic or Co-development Partner · 19 December 2025Partnered with Baxter and University Hospitals Coventry and Warwickshire NHS Trust to conduct environmental impact assessment comparing OPAT and inpatient administration care pathways for intravenous antimicrobial therapies.
• NHS South West Cardiovascular Clinical NetworkcoreImplementation/ SI/ Consulting PartnerJoint working agreement with NHS South West Cardiovascular Clinical Network to pool resources, skills and experience to benefit patients. Document available detailing the partnership terms.
• NHS England Wessex Cancer AlliancecoreImplementation/ SI/ Consulting PartnerJoint working agreement with NHS England Wessex Cancer Alliance to pool resources, skills and experience to benefit patients. Executive summary document available.
• AmericarescoreStrategic or Co-development PartnerHumanitarian aid partner that pre-positions Baxter products for times of crisis and addresses ongoing needs in underserved communities. Baxter International Foundation has committed donations to support relief efforts.
• Direct ReliefcoreStrategic or Co-development PartnerHumanitarian aid partner working with Baxter to pre-position products for crisis response and ongoing humanitarian needs in underserved communities.
• Partners In HealthcoreStrategic or Co-development PartnerHealthcare partner organisation working to improve access to healthcare in underserved communities through ongoing collaboration with Baxter.
• Partnership for Quality Medical Donations (PQMD)minorStrategic or Co-development PartnerBaxter is a proud member of PQMD, a unique alliance of non-profit and corporate organisations leading the development and championing of high standards in medical supply and service donation.
• Arthur Rank HospiceminorStrategic or Co-development PartnerBaxter International Foundation provided a grant of more than £59,000 to fund the Hospice@Home programme delivering daytime nursing to underserved populations in Fenland, Cambridgeshire.
• Horatio's GardenminorStrategic or Co-development PartnerBaxter International Foundation provided a grant of over £51,000 to fund the Head Gardener for two years at the newly opened garden at Stoke Mandeville Spinal Injuries Unit in Buckinghamshire.
• University College London (UCL)coreStrategic or Co-development PartnerBaxter funding established the Baxter Healthcare Scholarship to fund one undergraduate student in the Faculty of Engineering Sciences and one MSc student in the Global Business School for Health for 2024/2025 academic year, awarded based on financial need to UK students of Black-African or Black-Caribbean descent.
• Dublin City University Educational TrustcoreStrategic or Co-development PartnerBaxter funding offers five full- or part-time teaching masters postgraduate scholarships for the 2023/2024 academic year through its University of Sanctuary programme welcoming refugees and asylum seekers.
• Trinity College DublincoreStrategic or Co-development PartnerBaxter funding offers three scholarships to undergraduate ethnic minority students through Trinity Access Programme which aims to increase participation in higher education by students from underrepresented groups in Ireland.
• Baxter MultiCultural NetworkcoreOthersBaxter's Business Resource Group which promotes inclusion and belonging by embracing diversity among different dimensions of race, ethnicity and culture. Partnered with three higher-educational institutions in the UK and Ireland to support the Activating Change Today (ACT) scholarship initiative.
• Mayo CliniccoreStrategic or Co-development PartnerBaxter announced new research and clinical development collaboration with Mayo Clinic in 2017 as part of its commitment to nurturing a culture of innovation.
• Ramot at Tel Aviv University/Tel Aviv Sourasky Medical CentercoreStrategic or Co-development PartnerBaxter announced new research and clinical development collaboration with Ramot at Tel Aviv University and Tel Aviv Sourasky Medical Center in 2017 to bring innovative healthcare solutions.
• National Kidney FederationcoreStrategic or Co-development PartnerPatient organisation receiving financial support from Baxter UK for Peer Support Programme educating people considering home dialysis (£8,069 in 2023), patient event sponsorship (£2,500 in 2022), and Kidney Journey magazine advertisement (£4,043 in 2024).
• Kidney Care UKcoreStrategic or Co-development PartnerPatient organisation receiving £3,000 support in 2024 for the Kidney Care UK Dialysis Roadshow to benefit kidney disease patients.
• PINNT Patient Association for NutritioncoreStrategic or Co-development PartnerPatient organisation for people on intravenous and nasogastric nutrition therapy. Received £1,950 support in 2021 for collaborative project developing patient information materials on parenteral nutrition, and £260 in 2019 for feedback on prototype Home Parenteral Nutrition Pump.
• National VoicesminorStrategic or Co-development PartnerPatient organisation receiving £5,000 support in 2018 for National Voices Conference to advance patient advocacy and voice.
• The Patient AssociationminorStrategic or Co-development PartnerPatient organisation receiving £4,600 support in 2017 for the Empowerment Project to support patient self-advocacy and empowerment.
• American Hospital AssociationminorStrategic or Co-development PartnerBaxter sponsors the Foster G. McGaw Prize administered by AHA, which awards $100,000 to a winning healthcare organisation and $10,000 to three finalists for outstanding commitment to improving community health.
• Association for University Programs in Health Administration (AUPHA)minorStrategic or Co-development PartnerBaxter sponsors the William B. Graham Prize administered by AUPHA, a $50,000 award acknowledging national or international contributions of health services researchers.
• Sigma Theta Tau International (Nursing Honour Society)minorStrategic or Co-development PartnerBaxter sponsors the Episteme Award administered by Sigma, a $15,000 award given once every two years to recognise outstanding research conducted by a nurse.
• HillromcoreOthersBaxter completed acquisition of Hillrom for $10.5 billion (purchase price) / $12.5 billion enterprise value in December 2021, creating approximately $15 billion global medtech leader. Hillrom products include patient monitoring, diagnostic, and respiratory care devices. Integration aims to advance innovation in connectivity technology, digital health, and monitoring.

Scale indicators16 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Abbott: Diversified healthcare incumbent with medtech and nutritional divisions that overlap with Baxter's hospital care and clinical nutrition portfolios. Abbott competes in diagnostics, IV nutrition, and adjacent connected care categories.
• Medtronic: Global diversified medtech incumbent whose COO (Giuseppe Accogli) previously worked at Medtronic. Overlaps with Baxter in surgical, critical care, and patient monitoring segments, but operates across a much broader portfolio including cardiac and neuromodulation.
• Becton Dickinson (BD): Large diversified medical device company with overlapping offerings in infusion therapy, surgical instruments, IV drug delivery, and connected care. BD competes with Baxter across hospital care, surgical care, and home-based medication administration.
• Smith & Nephew: Surgical and wound care medtech incumbent with overlapping haemostatic, sealant, and tissue repair offerings (competing with FLOSEAL, TISSEEL, HEMOPATCH). Serves similar surgical theatres and NHS procurement frameworks as Baxter.
• Stryker: Diversified medtech incumbent with overlapping surgical care, critical care, and patient monitoring offerings (post-Hillrom integration Stryker and Baxter increasingly compete for OR and ICU capital equipment contracts).

Direct peers

• B. Braun: German-headquartered medtech manufacturer with overlapping portfolios in IV solutions, infusion systems, dialysis, surgical products, and clinical nutrition. B. Braun competes directly with Baxter across hospital care, nutritional care, and renal care product categories globally.
• Terumo: Japanese-headquartered medtech manufacturer with overlapping portfolios in infusion systems, IV solutions, blood collection, and surgical products. Terumo competes with Baxter in transfusion medicine, hospital care, and pharmaceutical-related device categories.
• ICU Medical: Specialist in smart infusion pumps and IV therapy safety solutions, directly competing with Baxter's Sigma pump line and broader infusion portfolio. ICU Medical focuses on medical connectors and infusion technology that overlap with Baxter's INTERLINK and V-LINK heritage.
• Fresenius Medical Care: Global leader in dialysis products and services, directly competing with Baxter's renal care portfolio across haemodialysis, peritoneal dialysis solutions, and home dialysis equipment. Both companies serve the same end-stage renal disease patient populations and NHS renal contracts.

Emerging players

• Edwards Lifesciences: Critical care-focused medtech company with meaningful overlap in ICU haemodynamic monitoring and patient monitoring. Partial overlap with Baxter's PRISMAX critical care ecosystem and Hillrom-derived monitoring products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/johnmuldoonas
• YouTubeyoutube.com/@VantiveHealth
• Facebookfacebook.com/Baxter-Healthcare-1281858861863341
• LinkedInlinkedin.com/company/baxter-uk
• Instagraminstagram.com/VantiveHealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baxter Healthcare